Lilly gets rare downgrade as analysts question hype over GLP-1 pills and Zepbound’s cash sales
The Big Market Report Take
If middle-class Americans lose their jobs to AI, that could mean fewer cash sales of weight-loss drugs like Zepbound.
Not financial advice. The Big Market Report aggregates news for informational purposes only. Nothing on this site constitutes investment advice. Equities and other securities are subject to market risk. Always do your own research and consult a qualified financial advisor before making any investment decisions. Full disclaimer →
Never miss a story
More from this section
JPMorgan Strategists Cut S&P 500 Target on Iran War UncertaintyBloomberg Markets24m ago- Super Micro: From Undervalued To UninvestableSeeking Alpha31m ago
- Target Hospitality Still Aims At Its Potential Core Recovery And Growth DriversSeeking Alpha36m ago
- Helios Technologies, Inc. (HLIO) Analyst/Investor Day - SlideshowSeeking Alpha39m ago
- F&G Annuities And Life: Addressing Market Fears Over Its Private Credit ExposureSeeking Alpha41m ago